Oncology Sales Farce

Quote












Anonymous said:
How much longer will this absurd joke of a sales farce be around with absolutely nothing to sell? Piss poor leadership and a dead product in Proleukin.
Click to expand...

It is unfortunate that you have such a low view of Proleukin, the only agent that can deliver the promise of a complete and durable response in selected patients with stage IV melanoma and renal cell carcinoma.

I promoted Proleukin at Novartis Oncology. Based on that experience, I suggest that when you make a call on an oncologist, deliver the key communication points about Proleukin with dedication and confidence. After your call, should the oncologist then see a candidate for Proleukin therapy and offers the treatment to that patient who has the will to live, then you will have made a real difference, and the patient may experience a long life that otherwise might have been forfeited.
 






Anonymous said:
It is unfortunate that you have such a low view of Proleukin, the only agent that can deliver the promise of a complete and durable response in selected patients with stage IV melanoma and renal cell carcinoma.

I promoted Proleukin at Novartis Oncology. Based on that experience, I suggest that when you make a call on an oncologist, deliver the key communication points about Proleukin with dedication and confidence. After your call, should the oncologist then see a candidate for Proleukin therapy and offers the treatment to that patient who has the will to live, then you will have made a real difference, and the patient may experience a long life that otherwise might have been forfeited.
Click to expand...

Man, what have you been smoking? Novartis played Prometheus for a sucker when they dumped this dog of a product on us. Ipilimumab (Yervoy) will kill what is left of Proleukin in the metastatic melanoma market. Like it or not, the oral TKIs are getting the bulk of the business in RCC. Wong says in his paper that Ipi will replace Proleukin. Proleukin is dead, and we better get our resumes ready. Our NSD is a tub of s--t who know nothing about Oncology.
 






Anonymous said:
Man, what have you been smoking? Novartis played Prometheus for a sucker when they dumped this dog of a product on us. Ipilimumab (Yervoy) will kill what is left of Proleukin in the metastatic melanoma market. Like it or not, the oral TKIs are getting the bulk of the business in RCC. Wong says in his paper that Ipi will replace Proleukin. Proleukin is dead, and we better get our resumes ready. Our NSD is a tub of s--t who know nothing about Oncology.
Click to expand...

Very well summarized.
 












Anonymous said:
Man, what have you been smoking? Novartis played Prometheus for a sucker when they dumped this dog of a product on us. Ipilimumab (Yervoy) will kill what is left of Proleukin in the metastatic melanoma market. Like it or not, the oral TKIs are getting the bulk of the business in RCC. Wong says in his paper that Ipi will replace Proleukin. Proleukin is dead, and we better get our resumes ready. Our NSD is a tub of s--t who know nothing about Oncology.
Click to expand...

Why are you still here then -- or are you just trolling this site because you have some ax to grind?
 












Anonymous said:
Man, what have you been smoking? Novartis played Prometheus for a sucker when they dumped this dog of a product on us. Ipilimumab (Yervoy) will kill what is left of Proleukin in the metastatic melanoma market. Like it or not, the oral TKIs are getting the bulk of the business in RCC. Wong says in his paper that Ipi will replace Proleukin. Proleukin is dead, and we better get our resumes ready. Our NSD is a tub of s--t who know nothing about Oncology.
Click to expand...

Wow, doesn't take much to get some people to run with their tail between their legs. IL-2 will not set the world afire in the future, but it will still offer patients a real chance for a durable response even with ipi in the market. To bad you believe the PR hype -- you might want to read the data. Whatever the case, if you really are someone on the sales side, you are destined to fail given your fear over reality viewpoint.
 






Anonymous said:
Wow, doesn't take much to get some people to run with their tail between their legs. IL-2 will not set the world afire in the future, but it will still offer patients a real chance for a durable response even with ipi in the market. To bad you believe the PR hype -- you might want to read the data. Whatever the case, if you really are someone on the sales side, you are destined to fail given your fear over reality viewpoint.
Click to expand...

Not the OP here; get a grip on reality, please. IL-2 has always been and will abe an extremely toxic agent, especially when administered IV, which is the only way to achieve those miraculous response rates you speak of. Its toxicity far outweighs any potential for cure that may exist in a small subset of patients, which is why even back in the day when IL-2 and interferon were the only options for RCC, few oncologists offerred them to patients. Same holds true for advanced melanoma, except there you had other systemic options such as DTIC, which of course does not have curative potential anyway. Lesson completed.
 






Anonymous said:
Wow, doesn't take much to get some people to run with their tail between their legs. IL-2 will not set the world afire in the future, but it will still offer patients a real chance for a durable response even with ipi in the market. To bad you believe the PR hype -- you might want to read the data. Whatever the case, if you really are someone on the sales side, you are destined to fail given your fear over reality viewpoint.
Click to expand...

Hey Dude/Ditz, I've been here since Oncology was formed. I took this job mainly for the diagnostics. Proleukin is dead. Patient has to have a performance status of 1 or 0 and then be in the hospital for 2 different 5 day stays and be near a CCU. Ipilimumab has better data and the TKIs own the 1st line RCC market. Wake up and smell the coffee. Our mgt sucks in the worst way. The only two halfway decent DMs are CK and JB. KC is a ditzy twit and JT is a micromanaging flunkie from Wyeth. RS was totally worthless. Get out while you can.
 






Anonymous said:
Hey Dude/Ditz, I've been here since Oncology was formed. I took this job mainly for the diagnostics. Proleukin is dead. Patient has to have a performance status of 1 or 0 and then be in the hospital for 2 different 5 day stays and be near a CCU. Ipilimumab has better data and the TKIs own the 1st line RCC market. Wake up and smell the coffee. Our mgt sucks in the worst way. The only two halfway decent DMs are CK and JB. KC is a ditzy twit and JT is a micromanaging flunkie from Wyeth. RS was totally worthless. Get out while you can.
Click to expand...

I totally agree with this post in terms of product and managers except that JE leads the worthless list. What a joke.
 
















































Top Bottom
Back
Quote